Allogeneic Stem Cell Therapy Falls Short on Stroke Outcomes

(MedPage Today) -- Bone marrow-derived allogeneic stem cell therapy shortly after ischemic stroke did not improve outcomes at 90 days, a phase II/III randomized clinical trial known as TREASURE found. The rate of excellent outcomes -- a composite...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news